PCM
BIOT

Penserra Capital Management’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Penserra Capital Management’s Portfolio BIOT Stock Details BIOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,486
Closed -$24K – 1390
2022
Q2 		$24K Buy
2,486
+375
+18% +$3.68K ﹤0.01% 1078
2022
Q1 		$20K Sell
2,111
-1,029
-33% -$10.1K ﹤0.01% 1264
2021
Q4 		$30K Buy
+3,140
New +$30.8K ﹤0.01% 1155

Other funds holding BIOT

GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CCP
Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return
RA
RiverPark Advisors New York $219M AUM 14.89% 1-Year Est. Return
CM
Cohanzick Management Pleasantville, New York $231K AUM 3.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Penserra Capital Management's BIOT Position: Q3 2022 in Review

Penserra Capital Management sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q3 2022, closing a stake of 2,486 shares — an estimated $24K sold.

Penserra Capital Management first reported a position in BIOT in Q4 2021 and held it in 3 quarters. The position peaked at $30K in Q4 2021. 69 funds tracked by Wall St. Rank hold BIOT as of Q3 2022.

  • Penserra Capital Management reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q3 2022 after selling out during the quarter.
  • Penserra Capital Management sold 2,486 Biotech Acquisition Company Class A Ordinary Shares shares in Q3 2022, an estimated $24K.
  • Penserra Capital Management first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q4 2021 and held it in 3 quarters.
  • Penserra Capital Management's Biotech Acquisition Company Class A Ordinary Shares position peaked at $30K in Q4 2021.
  • 69 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q3 2022.

Based on Penserra Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.